Tissue-engineered bone for treatment of combat related limb injuries by Vasyliev, R.G. et al.
Experimental Oncology 39, 191–196, 2017 (September) 191
TISSUE-ENGINEERED BONE FOR TREATMENT OF COMBAT 
RELATED LIMB INJURIES
R.G. Vasyliev1, 2, V.M. Oksymets2, A.E. Rodnichenko1, 2, A.V. Zlatska1, 2, O.S. Gubar2, 3, 
I.M. Gordiienko2, 4, D.O. Zubov1, 2,*
1State Institute of Genetic and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, 
Kyiv 04114, Ukraine
2Biotechnology Laboratory ilaya.regeneration, Medical Company ilaya®, Kyiv 03115, Ukraine
3Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv 03680, Ukraine
4R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
Aim: Based on our preliminary positive clinical results with use of cultured bone marrow-derived multipotent mesenchymal stem/stromal 
cells in traumatology, our aim was to develop living three-dimensional tissue-engineered bone equivalent transplantation technology for 
restoration of critical sized bone defects caused by combat related high energy trauma. Materials and Methods: To fabricate bone equivalent 
we used devitalized allogeneic bone scaffolds (blocks and chips) seeded with cultured autologous cells: bone marrow-derived multipotent 
mesenchymal stem/stromal cells in mix with periosteal progenitor cells and endothelial progenitor cells. Quality/identity of cell cultures 
was assured by donor and cell culture infection screening (immunofluorescence assay, polymerase chain reaction), flow cytometry (cell 
phenotype), karyotyping (GTG banding), functional assays (colony forming units analysis, multilineage differentiation assay). Bone defect 
treatment with bone equivalent application was fully completed in 39 combat-injured with 42 defects. New bone formation was assessed 
by the radiographic examination. Results: Casualties were included in a treatment program an average of 10.1 months after injury, provided 
the ineffectiveness of conventional surgery methods. All cell type cultures had a normal karyotype and appropriate phenotype, differentia-
tion potential and functional properties, ~30% colony forming units frequency and hadn’t any signs of cell senescence. The fluorescein 
diacetate/propidium iodide combined staining and histology analysis of graft samples before transplantation showed their regular seeding 
with viable cells. Pathomorphological analysis of bone equivalent specimens 3–6 months post-op revealed the active remodeling processes 
and immature bone tissue formation. Bone defect restoration was observed 5–6 months post-op. Conclusion: The developed biotechnology 
of living three-dimensional tissue-engineered bone equivalent transplantation with overall effectiveness 90.4% allows restoring the bone 
integrity, forming new bone tissue in a site of bone defect, and significantly reducing the rehabilitation period of a patient.
Key Words: regenerative medicine, bone defects, tissue-engineered bone equivalent, human cell-based medicinal products, multi-
potent mesenchymal stromal/stem cells, endothelial progenitor cells.
The problems of high energy traumatic injuries 
of skeleton bones and the methods of their recon-
struction in correlation with reparative osteogenesis 
are relevant for actual clinical and experimental trau-
matology and orthopedics. Temporary and economic 
costs for treating patients with alterations of reparative 
regeneration processes, especially in the high-energy 
mechanism of trauma, the complexity of their social 
adaptation, justify the need to search for innovative 
organ-saving technologies of regenerative medicine 
for bone integrity restoration. Particularly, it is actual 
the problem of treatment of combat related high energy 
bullet, shrapnel and blast injuries Ukrainian traumatolo-
gists faced with, seeing the military actions in eastern 
part of Ukraine.
The gold standard for extended bone defects’ 
treatment is autologous osteoplastic surgery. Then 
there are methods of the defect filling with use of dif-
ferent osteoplastic materials, such as allogeneic and 
xenogeneic bone (e.g., demineralized bone matrix); 
synthetic and polymer materials; and using the method 
of compression-distraction osteosynthesis by Ilizarov. 
The choice of the method of plastic of the bone defect 
depends on its location and size.
The newest alternative to the conventional methods 
of bone plastic surgery is bone restoration methods based 
on the approaches of regenerative medicine. Currently, 
there are two approaches to bone regene ration. The 
first one is based on the delivery of high doses of bone 
morphogenetic and other factors to the defect zone, 
such as autologous platelet concentrate or recombinant 
bone morphogenetic proteins (BMPs). Marx et al. [1] first 
evaluated the use of platelet concentrate for bone healing 
in 1998, and his studies led to the development of an entire 
industry for its use in traumatology and orthopedics using 
platelet concentrator devices. BMPs were first proposed 
as bone morphogenes by Urist in 1965 [2]. In the late 
1980s his team performed the first transplantation with 
their use [2, 3].
The second approach in bone regeneration is based 
on the delivery to the defect area of the critical mass 
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of osteoprogenitor cells, which realize their trophic and 
integrative potencies in a wound for the formation of bone 
regenerate and new bone at final. For the first time Phe-
mister in the 1940s used injections of bone marrow aspi-
rate into the fracture non-unions [4]. In the 1960s Burwell 
proposed as an autograft of the iliac crest bone containing 
the bone marrow [5]. Subsequently, as a source of os-
teoprogenitor cells, a concentrated bone marrow-derived 
mononuclear fraction was used. Connolly first showed 
in 1998 that four-fold concentration of the mononuclear 
fraction of bone marrow significantly increases the 
degree of fusion of non-consolidated fractures in hu-
mans [6]. Muschler et al. in 2003 proposed the technique 
of saturation of allogeneic bone chips and crumbs with 
a bone marrow clot, both in animal models and in clinical 
practice of fracture consolidation [7, 8]. After preclinical 
studies of Muschler’s technique, on a par with autograft 
application, the positive results of its effectiveness were 
confirmed by several completed multicenter clinical trials 
[9, 10]. However, in some cases, neither the autograft 
nor Muschler’s technique led to the formation of a dense 
bone in non-consolidated fractures revealed by the X-ray 
examination. Such dysfunction may be related to the 
individual osteogenic insufficiency of bone marrow cells, 
as well as to the compromised immune status of the pa-
tient. Thereby, the next step in bone regeneration was the 
use of immunomodulatory allogeneic cultured osteopro-
genitor bone marrow-derived multipotent mesenchymal 
stromal/stem cells (BM-MSCs) [11–14]. Of note, the 
organ-saving bone regeneration technology Trinity Evolu-
tion™ (Orthofix, USA) based on Mushler’s approach has 
been proposed to restore defects in casualties with com-
bat related trauma obtained in Iraq and Afghanistan war 
conflicts. As an osteoinductive scaffold the authors from 
Walter Reed National Military Medical Center (Bethesda, 
USA) have used the allogeneic demineralized bone matrix 
chips pre-saturated with allogeneic cadaver mononuclear 
fraction of bone marrow containing uncultured and non-
purified MSCs [15]. Furthermore, in other studies for bone 
fracture consolidation, it was applied an alternative cell 
component — the adipose-derived MSCs, or adipose-
derived stem cells (ADSCs) [16, 17].
Considering the safety profile of cell therapies, it was 
explored a recent review analyzing 70 clinical studies 
worldwide with more than 1400 patients involved and 
treated with autologous or allogeneic adipose-derived 
MSCs. Thus, in case of allogeneic use it was shown the 
generation of specific antibodies towards donor cells 
in 19–34% of patients with not yet well known systemic 
impact. Concerning the oncological safety, only one case 
of breast cancer recurrence was noted out of 121 previ-
ous breast cancer patients within the 12-month follow-
up periods. In other three trials examined with 32 previous 
prostate cancer patients involved, no cancer recurrences 
were found within 3 to 6 months follow-up period [18].
Our biotechnology approach to bone integrity res-
toration is based on the transplantation of a living three- 
dimensional tissue-engineered bone equivalent (3D TEBE) 
developed by our R&D group since 2004 in Ukraine [19, 
20]. In its last modification the advanced 3D TEBE 
consists of decellularized allogeneic bone block of the 
required size and shape (for circular defects), or bone 
chips or crumbs (for tangential defects). These scaffolds 
are used as osteoinductive and osteoconductive carriers 
for cultured autologous osteoprogenitor BM-MSCs and 
periosteal progenitor cells (PPCs) intended for formation 
of the critical cell mass for new bone formation in situ, and 
endothelial progenitor cells (EPCs) from patient’s own 
peripheral blood intended to enhance the vascularization 
and trophics of the manufactured 3D TEBE.
MATERIALS AND METHODS
Casualties. The forty seven casualties were included 
for a moment into the experimental treatment program 
assured by the Medical company ilaya® Bioethics Com-
mission permission, patient’s informed consent, local 
protocol for treatment approved by the Ministry of Health 
of Ukraine; 39 injured patients with 42 bone defects have 
been completely treated. Selected patients hadn’t previ-
ous oncologic diseases reported and possessed circular 
and tangential critical sized defects (ones without spon-
taneous recovery throughout life, more than 3.0 cm) 
of tubular bones and heel bone of various lengths and 
volume. The defects were allocated according to the 
Table 1. Assessment of the effectiveness of a treatment 
was performed by the X-ray examination over 3 and 
6 months after grafting. In some cases, during the 3D 
TEBE adaptive resection surgery the extra fragments 
of the remodeling graft was taken, which was subse-
quently subjected to the pathomorphological analysis 
(e.g., 6 months after grafting, human cells). The sections 
were stained with hematoxylin & eosin.
Cell cultures
Culture of the BM-MSCs. Heparinized bone marrow 
aspirate in a volume not more 5 ml was obtained with 
an aspirating needle from the patient’s iliac crest. Then, 
1 ml of aspirate was spread over culture flasks with an area 
of 175 cm2 (SPL, Korea). The primary culture was seeded 
into multi-flasks with an area of 875 cm2 (Corning, USA) for 
large scale cell expansion. The therapeutic dose of BM-
MSCs (50–300•106 cells) was available over 30–40 days.
Culture of osteoprogenitor PPCs. A culture of PPCs 
was obtained from a minimal fragment of the fibula 
periosteum up to 1 cm3. The fragment was washed with 
antibiotic/antimycotic solution (BioWest, France) and 
poured into the 100 mm Petri dish (SPL, Korea). The 
primary culture was seeded into multi-flasks with an area 
of  875 cm2 (Corning, USA). The therapeutic dose of PPCs 
(20–60•106 cells) was available over 30 days.
The growth medium for BM-MSCs and PPCs cultur-
ing consists of α-MEM, 10% fetal bovine serum (FBS), 
1 ng/ml bFGF (Sigma-Aldrich, USA), 2 U/ml heparin 
sodium (Indar, Ukraine), 100 U/ml antibiotic-antimycotic 
solution (BioWest, France). Cell subculturing was car-
ried out with a mixture of trypsin and EDTA solutions 
in a ratio of 0.05%:0.02% in phosphate buffered saline 
(PBS) (Sigma-Aldrich, USA). The seeding density was 
103 cells per 1 cm2.
Culture of EPCs from the peripheral blood. EPCs were 
obtained from 20 ml of heparinized venous blood of the 
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patient. Each 5 ml blood was spread per 75 cm2 culture 
flask (SPL, Korea) into the selective endothelium growth 
medium EGM-2 (Lonza, Italy). Single EPCs colonies from 
the primary culture were seeded in culture flasks with 
an area of 175 cm2 (SPL, Korea) to obtain a therapeutic 
dose. Cell subculturing was carried out with a mixture 
of trypsin and EDTA solutions in a ratio of 0.1%:0.02% 
in PBS (Sigma-Aldrich, USA). The seeding density was 
3•103 cells per 1 cm2. The therapeutic dose of EPCs 
(20–60•106 cells) was available over 30 days.
All of the above cell types were grown in a multi-gas 
incubator (Binder CB 210, Germany) in an atmosphere 
of 5% CO2 and 5% O2 and a saturating humidity of 97%.
All patients (peripheral blood — by immunofluores-
cence assay, polymerase chain reaction) and finalized 
cell cultures (by polymerase chain reaction) were 
screened for absence of HIV ½, HBV, HCV, HSV ½, 
CMV, EBV, Treponema pallidum and Mycoplasma ssp.
Functional assays for quality control. A set of qual-
ity control procedures were established to release per-
sonalized 3D TEBE as the human cell-based medicinal 
product. To determine the cell plating efficiency, colony 
forming units (CFU) analysis was performed according 
to the conventional protocol. For CFU staining, the cell 
colonies were fixed with cold ethanol and stained with 
azure-eosin by Romanowsky (Makrokhem, Ukraine) for 
20 min [21]. Multilineage differentiation into the osteo-
genic and adipogenic directions was carried out according 
to the standard protocols [22]. Alkaline phosphatase (ALP) 
detection was carried out by the BCIP/NBT substrate as-
say (Sigma-Aldrich, USA). The normal karyotype of cul-
tured cells was confirmed by GTG banding method [21].
Directed multilineage differentiation assays
Adipogenic differentiation was performed in the 
following medium: DMEM-HG (4.5 g/l) supplemented 
with 10% FBS, 1 µM dexamethasone, 200 µM indo-
methacine, 500 µM isobutylmethylxanthine, 5 µg/ml in-
sulin (Sigma-Aldrich, USA) and 5% donor horse serum 
(BioWest, France). After 14 days the cells were fixed and 
stained. To detect the adipogenic differentiation, the 
cells were stained with 0.5% solution of Oil Red O dye 
for neutral intracellular lipids (Sigma-Aldrich, USA) [22].
Osteogenic differentiation was performed in the follow-
ing medium: DMEM low glucose (1.0 g/l) with 10% FBS, 
100 nM dexamethasone, 10 mM β-glycerophosphate and 
50 µg/ml ascorbate-2-phosphate (Sigma-Aldrich, USA). 
After 21 days the cells were fixed and stained. To detect 
osteogenic differentiation, the cells were stained with 2% 
solution of Alizarin Red S dye for calcified extracellular 
matrix deposition (Sigma-Aldrich, USA) [22].
Endothelial cell tube formation assay. The assay 
measures the ability of endothelial cells, plated at sub-
confluent densities with the appropriate extracellular 
matrix support, to form capillary-like structures (tubes). 
The EPCs were added to the Matrigel™ Matrix-coated 
(Corning, USA) well of 24-well plate (SPL, Korea) at the 
density 103 cells per 200 µl, at a final medium volume 
of 200 µl per 1 cm2 per well. Then they were incubated 
at 37 °C, 5% CO2, 5% O2 overnight in selective endothe-
lium growth medium EGM-2 (Lonza, Italy). EPCs develop 
well-formed tube networks within 4–6 hours [23].
Flow cytometry. The number of positive and 
negative cells for corresponding markers (conven-
tional, but not all-sufficient set) [14, 22] was mea-
sured for cultured BM-MSCs, PPCs and EPCs (at P2, 
n = 5 per cell type) with use of flow cytometer BD FACSAria 
(BD Biosciences, USA). Staining with the monoclonal 
antibodies (PerCP-Cy5.5 mouse anti-human CD105, 
APC mouse anti-human CD73, FITC mouse anti-human 
CD90, PerCP-Cy5.5 mouse anti-human HLA-DR, 
PE-Cy-7 mouse anti-human CD31, PE mouse anti-human 
CD271, APC mouse anti-human CD34, FITC mouse anti-
human CD45) was performed according to the manufac-
turer’s instructions (BD Pharmingen, BD Horizon, USA).
3D TEBE manufacturing. As a scaffold for cells, 
a treated, cell-, DNA-free, allogeneic and non-immu-
nogenic bone blocks of the required size and shape, 
bone chips and bone crust were used (A.A. Partners 
Ltd., Ukraine). In a first step the carrier was seeded 
directly with cells; in a second step the cell-seeded 
carrier was placed into the fibrin-derived hydrogel, also 
containing the cells. Cells were seeded over a carrier 
and into the fibrin hydrogel at a ratio of 2–5•106 cells per 
1 cm3 scaffold. If the bone defect did not exceed 3 cm, 
then the equivalent with only cultured BM-MSCs was 
used; if more than 5 cm — BM-MSCs and PPCs were 
used at a ratio of 3:1; if more than 7 cm — BM-MSCs, 
PPCs and EPCs were applied in a ratio of 3:1:1. The ap-
propriately seeded 3D TEBE before the transplantation 
was incubated for 5–14 days according to the size and 
volume in the BM-MSCs growth medium in a multi-gas 
incubator (Binder CB 210, Germany) in an atmosphere 
of 5% CO2 and 5% O2 and a saturating humidity of 97%. 
The quality and regularity of seeding of the equivalent 
fragment with cells were confirmed by the combined 
staining with fluorescein diacetate/propidium iodide 
(FDA/PI) fluorescent dyes (Sigma-Aldrich, USA).
Microscopy. Inverted fluorescent microscope 
AxioObserver A1 equipped with digital camera AxioCa-
mERc 5s and ZEN 2012 software (Carl Zeiss, Germany) 
were applied.
Statistics. The data are presented as mean and 
SEM (M ± m). Statistical significance was estimated 
using the Student’s t-criterion.
RESULTS AND DISCUSSION
The gold standard for critical sized bone defect 
restoration is autologous bone graft transplantation. 
Although this surgery possesses its drawbacks, such 
as morbidity, risk of donor wound contamination and 
non-healing, risk of lysis of transplanted bone autograft. 
As a substantial alternative for autologous bone grafting 
we developed the regenerative medicine organ-saving 
biotechnology of the 3D TEBE transplantation.
The total number of treated casualties using tissue 
engineering approach was 47 (male — 46, female — 
1). The treatment was completed in 39 patients. Forty 
seven wounded persons had critical sized bone de-
fects of different location (Table 1). Eight patients are 
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in the treatment course. The age of the patients was 
21–48 years (the average age is 33.9 years). Before 
entering the clinic course, the wounded persons were 
subjected to 2–27 surgeries (an average of 5.7 sur-
geries). The patients came in treatment 2–22 months 
(an average of 10.1 months) after the combat related 
injury and unsuccessful surgeries in other foreign and 
Ukrainian hospitals. Most casualties had received a pre-
scription to the limb amputation.
Table 1. Total number of patients and allocation of critical sized bone de-
fects in casualties subjected to 3D TEBE transplantation
Bone defect 
allocation Arm Forearm Femur Shin Heel
Total
n %
Proximal third 4 − 2 6 − 12 25.5
Diaphysis 5 5 8 10 − 28 59.6
Distal third 3 − − 1 − 4 8.5
Calcaneus − − − − 3 3 6.4
Total 12 5 10 17 3 47 100.0
Transplantation of 3D TEBE in the form of bone 
blocks was performed in 10 wounded, in the form 
of chips — in 22 wounded, and in the form of bone 
blocks and chips — 13 casualties. The volume of the 
transplant ranged from 10 to 180 cm3 (on the average 
40.4 cm3). The average density of graft seeding was 
4.7 million cells per 1 cm3. The manufactured bone 
equivalent was homogenously seeded with cells after 
incubation on a scaffold as proved by FDA/PI combined 
staining procedure. The cell cultures were appropriately 
characterized for their identity, purity, potency, viability 
and suitability for the intended use [14, 22, 23]. All cell 
cultures had a normal karyotype and phenotype, dif-
ferentiation potential and functional properties, ~30% 
CFU frequency and hadn’t any signs of cell senescence.
Cultured BM-MSCs and PPCs were positive for 
conventional (but not unique) stromal markers CD105, 
CD90, CD73, negative (< 2%) by hematopoietic markers 
CD34, CD45, and negative for MHC class II molecules — 
HLA-DR (Table 2). Cultured PPCs were also positive for 
CD271 (a versatile pre-culture marker, reported to be ex-
pressed only on isolated, but not cultured adult MSCs 
to selectively isolate and expand the adult stromal cells 
with both immunosuppressive and lympho-hematopoietic 
engraftment-promoting properties) [24]. Cultured EPCs 
were highly positive for CD31 (key endothelial marker), 
CD105 and CD73, positive for CD34 (~35%), and negative 
for CD45 and HLA-DR. It is interesting to observe the ex-
pression of the CD90 stromal marker on in vitro expanded 
EPCs being low as 3.4% (see Table 2).
Table 2. Positive and negative cell surface markers of all cultured cell 
types involved in 3D TEBE manufacturing (determined by flow cytometry). 
Data presented as a percentage of parent population, %
Cell cul-
ture CD105 CD90 CD73 CD271 CD31 CD34 CD45
HLA-
DR
BM-MSC 99.7 ± 
0.1
95.6 ± 
1.2
99.8 ± 
0.0
ND ND 0.4 ± 
0.1
0.4 ± 
0.1
0.8 ± 
0.3
PPCs 97.5 ± 
1.7
97.7 ± 
1.4
99.4 ± 
0.4
29.7 ± 
3.7
ND 1.1 ± 
0.6
0.3 ± 
0.1
1.6 ± 
0.6
EPCs 99.2 ± 
0.3
3.4 ± 
1.4
99.6 ± 
0.2
ND 99.2 ± 
0.1
35.0 ± 
11.7
0.7 ± 
0.2
2.7 ± 
1.2
Note: at P2, n = 5; ND — not determined.
Of note, only PPCs, but not BM-MSCs cultures 
at their basal culture level were ALP positive. Moreover, 
the PPCs cultures failed their adipogenic differen-
tiation assay after 14 days of induction. It means the 
strong osteogenic commitment of this cell type without 
directed osteogenic induction in vitro (Fig. 1).
Histological analysis of 3D TEBE biopsies taken 
during graft adaptation resection surgery 3–6 months 
after transplantation showed graft intensive remodel-
ing and immature bone tissue formation (Fig. 2).
Restoration of the bone defects was observed after 
5–6 months post-op and evaluated by radiographic ex-
amination in 39 patients (42 critical sized bone defects). 
The results of the treatment are done in the Table 3 and 
considered as the following: Good — the formation 
Fig. 1. Cell cultures’ functional assays for QC: a — BM-MSCs 
(morphology, immunophenotype, karyotype, directed diffe-
rentiation assay); b — PPCs (morphology, immunophenotype, 
directed differentiation assay, BCIP/NBT for ALP detection); c — 
EPCs (morphology, immunophenotype, karyotype, endothelial 
cell tube formation assay in Matrigel™ Matrix)
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of bone tissue with the restoration of the integrity of bone 
segments of a limb within 4–6 months post-op (Fig. 3); 
Satisfactory — patients who had partial graft lysis in the 
transplantation area, but bone was formed provided the 
functional capacity of injured limb; patients who expe-
rienced a delay (more than 6 months) for bone tissue 
formation post-op; Unsatisfactory — patients who had 
a complete lysis of the transplanted bone equivalent. 
Thereof, the overall effectiveness of treatment of critical 
sized bone defects with 3D TEBE was 90.4%.
Table 3. The results of completed critical sized bone defects’ treatment 
with use of 3D TEBE
Results n %
Good 30 71.4
Satisfactory 8 19.0
Unsatisfactory 4 9.6
Total 42 100
Note: 39 patients with 42 critical sized bone defects.
The biomedicinal product based on the human 
cells developed by our group can be attributed, 
depending on the main regulatory systems (Euro-
pean Medicines Agency — Committee for Advanced 
Therapies, EU vs Food and Drug Administration, USA) 
either to the (1) “Human Cell-Based Medicinal Prod-
ucts” — in terms of the European Medicines Agency 
[25], or to the (2) “Human cells, tissues, and cellular 
and tissue-based products”, those in terms of the 
Food and Drug Administration [26]. Seeing the signing 
of the Association agreement between Ukraine and the 
European Union in 2014, our legislation and regulatory 
on the transition of biomedicinal product based on hu-
man cells into the clinical practice should be gradually 
harmonized with the EU legislation.
Based on our developed method for treatment 
of critical sized bone defects with the use of re-
generative medicine approaches, we have planned 
and registered the clinical study at the International 
Registry ClinicalTrials.gov entitled “3D Tissue Engi-
neered Bone Equivalent for Treatment of Traumatic 
Bone Defects (3D TEBE)”; ClinicalTrials.gov Identifier: 
NCT03103295. ClinicalTrials.gov is a registry and re-
sults information database of clinical research studies 
sponsored or funded by a broad range of public and 
private organizations around the world [27].
Thereof, the developed regenerative medicine 
approach to organ-saving transplantation of the liv-
ing 3D TEBE, with the overall effectiveness of 90.4%, 
allows restoring the bone integrity, forming new bone 
tissue in a site of bone defect of critical size, and sig-
nificantly reducing the rehabilitation period of a patient.
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